What is the mechanism of action of GLP-3 (Retatrutide-class)?

Single molecule activating GLP-1, GIP, and glucagon receptors. GLP-1 suppresses appetite and stimulates insulin; GIP contributes to insulin sensitization and adipose lipolysis; glucagon-receptor activation contributes to energy expenditure increase. Net effect: appetite suppression + thermogenesis. For female hormonal and cyclical applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Single molecule activating GLP-1, GIP, and glucagon receptors. The female physiology interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What does GLP-3 (Retatrutide-class) stack well with?

For female physiology protocols, GLP-3 (Retatrutide-class) pairs with compounds on complementary pathways: Oxytocin, Kisspeptin, GHK-Cu. These pairings are selected because they engage independent receptor systems from GLP-3 (Retatrutide-class)'s primary mechanism (Single molecule activating GLP-1, GIP, and glucagon receptors), producing additive or synergistic effects rather than receptor competition.

Is GLP-3 (Retatrutide-class) safe during pregnancy or breastfeeding?

GLP-3 (Retatrutide-class), like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

How does GLP-3 (Retatrutide-class) interact with female hormonal cycling?

Cyclical hormone background influences how GLP-3 (Retatrutide-class) is distributed, metabolised, and felt. Even where the compound's pharmacology is not directly hormonal, response often varies across follicular and luteal phases. Premenopausal users should track by cycle phase for 1–2 cycles before settling on a fixed schedule; perimenopausal users benefit from integration with HRT where indicated.

Should I cycle GLP-3 (Retatrutide-class)?

Standard cycle for GLP-3 (Retatrutide-class) is 8–12 weeks of 1x weekly subq Trial doses 1-12 mg weekly dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to GLP-3 (Retatrutide-class)'s ~6 days half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Home/ Compounds/ GLP-3 (Retatrutide-class)

GLP-3 (Retatrutide-class)

Women's Health

Cycle-aware, fertility-aware, perimenopause-aware: GLP-3 (Retatrutide-class) is evaluated by women's-health clinicians on multiple axes. Single molecule activating GLP-1, GIP, and glucagon receptors GLP-1 suppresses appetite and stimulates insulin; GIP contributes to insulin sensitization and adipose lipolysis; glucagon-receptor activation contributes to energy expenditure increase. Net effect: appetite suppression + thermogenesis.. The compound's triple-incretin receptor agonist pharmacology produces measurable effects on the systems women's-health practice cares about — cycle regularity, mood, bone density, cardiovascular tone, and the perimenopausal transition. Each is examined in the sections below.

Female Physiology Applications

PerimenopauseMood (Cycle-Related)Libido (Female)SleepFertility

Key Takeaways

Female-physiology lens: GLP-3 (Retatrutide-class) response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Single molecule activating GLP-1, GIP, and glucagon receptors.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: Trial doses 1-12 mg weekly 1x weekly subq via subq; cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Single molecule activating GLP-1, GIP, and glucagon receptors. GLP-1 suppresses appetite and stimulates insulin; GIP contributes to insulin sensitization and adipose lipolysis; glucagon-receptor activation contributes to energy expenditure increase. Net effect: appetite suppression + thermogenesis. For women's-health applications, the mechanism is evaluated against cyclical context, fertility implications, bone remodelling, and cardiovascular tone. GLP-3 (Retatrutide-class)'s contribution to each varies; the subsections below work through these in turn.

Cyclical and hormonal context

Female physiology is cyclical in a way that male physiology is not, and GLP-3 (Retatrutide-class)'s effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.

Fertility and reproductive considerations

GLP-3 (Retatrutide-class)'s effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. GLP-3 (Retatrutide-class)'s effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Female Physiology Applications

Perimenopause

In the perimenopausal window, GLP-3 (Retatrutide-class) for perimenopause produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Fertility

For fertility in female users, GLP-3 (Retatrutide-class) is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Cognitive (Cycle/Menopause)

Cognitive (Cycle/Menopause) is one of the dimensions on which women track GLP-3 (Retatrutide-class) response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Hair Health

In the perimenopausal window, GLP-3 (Retatrutide-class) for hair health produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	Trial doses 1-12 mg weekly	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	Trial doses 1-12 mg weekly	4–6 weeks initial cycle
Women's Health focus	SubQ	Trial doses 1-12 mg weekly	1x weekly SubQ
Maintenance phase	SubQ	Trial doses 1-12 mg weekly	Ongoing with periodic pauses

Dose timing for GLP-3 (Retatrutide-class) is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

GLP-3 (Retatrutide-class) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

GLP-3 (Retatrutide-class) + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with GLP-3 (Retatrutide-class)'s mechanism in female physiology protocols.
GLP-3 (Retatrutide-class) + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with GLP-3 (Retatrutide-class)'s mechanism in female physiology protocols.
GLP-3 (Retatrutide-class) + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with GLP-3 (Retatrutide-class)'s mechanism in female physiology protocols.
GLP-3 (Retatrutide-class) + Epithalon: Identified by Khavinson in St. Pairs naturally with GLP-3 (Retatrutide-class)'s mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Investigational (Phase III for obesity) Research: Phase II completed; Phase III enrolling

GI events similar to semaglutide. Heart rate elevation observed. Long-term safety pending.

Lens-specific safety considerations for female physiology use of GLP-3 (Retatrutide-class): GI events similar to semaglutide. Heart rate elevation observed. Long-term safety pending. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Retatrutide triple receptor agonist Phase II in obesity

PMID 37364065

Supporting

Retatrutide in type 2 diabetes Phase II

PMID 37272677

GLP-3 (Retatrutide-class) vs Related Peptides

Compound	Profile	Onset	Best For
GLP-3 (Retatrutide-class)	Triple-incretin receptor agonist	~6 days	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Will GLP-3 (Retatrutide-class) affect contraceptive efficacy?

For most peptide compounds, contraceptive efficacy is not significantly affected. Compounds directly modulating the HPG axis (kisspeptin, gonadorelin) are exceptions and warrant alternative or additional contraceptive measures during use. GLP-3 (Retatrutide-class)'s specific interaction follows its mechanism.

How will GLP-3 (Retatrutide-class) interact with my cycle?

For pre-menopausal users, response to GLP-3 (Retatrutide-class) often varies across follicular and luteal phases. The first 1–2 cycles should be used to track response by phase before settling on a fixed schedule. Even where the compound's pharmacology is not directly cyclical, metabolism and felt response shift across the cycle.

Is GLP-3 (Retatrutide-class) appropriate during perimenopause?

Yes, and many women report stronger response in the perimenopausal window than at younger ages. The interaction with HRT — estrogen, progesterone, sometimes testosterone — is generally additive rather than competitive. Bone density, cardiovascular, and metabolic monitoring continues to apply.

Can I use GLP-3 (Retatrutide-class) alongside HRT?

Yes, in most cases. Integration with HRT — estrogen, progesterone, sometimes testosterone — is additive rather than competitive for most peptide compounds. Coordinating with a HRT-prescribing physician on dose timing and monitoring is the standard approach.

What is the standard dosing protocol for GLP-3 (Retatrutide-class)?

Conventional GLP-3 (Retatrutide-class) dosing is Trial doses 1-12 mg weekly 1x weekly subq via subq. For female hormonal and cyclical use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What route should I use for GLP-3 (Retatrutide-class)?

GLP-3 (Retatrutide-class) is delivered by subq. Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

Clinical Protocol

Start a GLP-3 (Retatrutide-class) Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified GLP-3 (Retatrutide-class) and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: ~4800 Da
Half-life: ~6 days
WADA: Not on prohibited list
FDA: Investigational (Phase III for obesity)
Research: Phase II completed; Phase III enrolling

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for GLP-3 (Retatrutide-class) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for GLP-3 (Retatrutide-class)

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised